AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021
Shots:
- The P-III SELECT-PsA 1 & 2 trials evaluate Rinvoq (15/30mg) vs PBO in patients with active PsA & axial involvement who have a history of intolerance or inadequate response to one non-biologic & biologic DMARD
- The results showed a greater clinical response related to axial across both studies compared to Humira across all BASDAI & ASDAS EPs in SELECT-PsA 1 @24wks. & proportion of patients achieve ASDAS CII (69.8% vs 54.1%). The safety profile was consistent with previously reported studies & no new safety risks were observed
- Rinvoq (15mg) has received the US FDAs approval for RA & ECs approval for RA, PsA & AS. The therapy has received ECs approval for 15 & 30mg doses to treat AD
Ref: PR Newswire | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com